SynBioBeta Speaker

Deena Emera

Buck Institute

Senior Scientist

Deena Emera, PhD, is an evolutionary biologist, author, and teacher. She earned a bachelor’s degree in Integrative Biology from UC Berkeley, a master’s degree in Physical Anthropology from NYU, and a PhD in Ecology and Evolutionary Biology from Yale. She has focused much of her career on the evolution of female biology, currently investigating the genetic basis of reproductive longevity in female whales at the Buck Institute’s Center for Healthy Aging in Women. Deena is also committed to science communication, writing articles and being featured in news outlets such as the Boston Globe and Time magazine, and recently publishing a book. In A Brief History of the Female Body (Sourcebooks, 2023), Deena draws on her expertise as a biologist and experience as a mother of four to explore the mysteries of the female body through an evolutionary lens.

Sessions Featuring

Deena

This Year

Femtech

•

12:00 PM

-

12:45 PM

Human Health

Engineering Reproduction

From AI-powered drug discovery to genomic selection and ovarian longevity — one of the most technically complex and ethically charged frontiers in biotech.The biology of reproduction has always carried the weight of the human story. Now it carries the weight of the possible.Ovarian aging is being mapped at the molecular level. Genomic selection is moving from research settings into clinical practice. AI is accelerating drug discovery for conditions that have been chronically underfunded and chronically misunderstood. The tools exist. The data is accumulating. The ethical frameworks are being written in real time — by the scientists in this room.

Featuring

Aristea Grammoustianou

Impli AG

Biosensor Tech Dev Lead

Lauren Avenius

Node Labs

CEO

Deena Emera

Buck Institute

Senior Scientist

Maria Lence

For Women's Health

CEO & Founder

Carmen Messerlian

Vie Science

CEO & Founder

Femtech

•

12:00 PM

-

12:45 PM

Human Health

Engineering Reproduction

From AI-powered drug discovery to genomic selection and ovarian longevity — one of the most technically complex and ethically charged frontiers in biotech.The biology of reproduction has always carried the weight of the human story. Now it carries the weight of the possible.Ovarian aging is being mapped at the molecular level. Genomic selection is moving from research settings into clinical practice. AI is accelerating drug discovery for conditions that have been chronically underfunded and chronically misunderstood. The tools exist. The data is accumulating. The ethical frameworks are being written in real time — by the scientists in this room.

Featuring

Aristea Grammoustianou

Impli AG

Biosensor Tech Dev Lead

Lauren Avenius

Node Labs

CEO

Deena Emera

Buck Institute

Senior Scientist

Maria Lence

For Women's Health

CEO & Founder

Carmen Messerlian

Vie Science

CEO & Founder

Femtech

•

12:00 PM

-

12:45 PM

Human Health

Engineering Reproduction

From AI-powered drug discovery to genomic selection and ovarian longevity — one of the most technically complex and ethically charged frontiers in biotech.The biology of reproduction has always carried the weight of the human story. Now it carries the weight of the possible.Ovarian aging is being mapped at the molecular level. Genomic selection is moving from research settings into clinical practice. AI is accelerating drug discovery for conditions that have been chronically underfunded and chronically misunderstood. The tools exist. The data is accumulating. The ethical frameworks are being written in real time — by the scientists in this room.

Featuring

Lauren Avenius

Node Labs

CEO

Aristea Grammoustianou

Impli AG

Biosensor Tech Dev Lead

Maria Lence

For Women's Health

CEO & Founder

Deena Emera

Buck Institute

Senior Scientist

Carmen Messerlian

Vie Science

CEO & Founder

Femtech

•

12:00 PM

-

12:45 PM

Human Health

Engineering Reproduction

From AI-powered drug discovery to genomic selection and ovarian longevity — one of the most technically complex and ethically charged frontiers in biotech.The biology of reproduction has always carried the weight of the human story. Now it carries the weight of the possible.Ovarian aging is being mapped at the molecular level. Genomic selection is moving from research settings into clinical practice. AI is accelerating drug discovery for conditions that have been chronically underfunded and chronically misunderstood. The tools exist. The data is accumulating. The ethical frameworks are being written in real time — by the scientists in this room.

Featuring

Lauren Avenius

Node Labs

CEO

Aristea Grammoustianou

Impli AG

Biosensor Tech Dev Lead

Maria Lence

For Women's Health

CEO & Founder

Deena Emera

Buck Institute

Senior Scientist

Carmen Messerlian

Vie Science

CEO & Founder

Previous Speakers Include